Medication Error Reporting - NAPLEX

1. A 68-year-old woman (60 kg, 160 cm) is discharged with a new prescription for levofloxacin 750 mg by mouth daily for 7 days for pneumonia. Current medications: metformin 500 mg twice daily and lisinopril 10 mg daily. Labs: serum creatinine 2.1 mg/dL (reference 0.6–1.3), estimated creatinine clearance 22 mL/min, alanine aminotransferase 18 U/L (reference 7–56). Allergy: none known. The prescription was entered and verified without renal dose adjustment. What is the most critical error in this scenario?
   Answer: Incorrect dose: levofloxacin was not adjusted for renal impairment (creatinine clearance 22 mL/min) Medication error identification and reporting focus on detecting lapses in dose adjustments, particularly for renally cleared drugs, to prevent toxicity and ensure patient safety. The key patient-specific factor is the patient's impaired renal function with a creatinine clearance of 22 mL/min, requiring dose reduction for levofloxacin. Choice B best addresses the error as it identifies the failure to adjust levofloxacin dosing for renal impairment, increasing the risk of adverse effects like seizures or tendon rupture. Choice A is incorrect because height documentation is not critical for this scenario, and choice C is suboptimal as azithromycin substitution isn't warranted solely due to diabetes without infection specifics. Choice D is wrong since INR monitoring is irrelevant for levofloxacin, which doesn't affect coagulation. For similar errors, pharmacists should calculate creatinine clearance for all renally adjusted medications and verify doses against guidelines like the product labeling. Implementing automated alerts in pharmacy systems and reporting errors can enhance vigilance and reduce harm in vulnerable populations.
2. A 74-year-old woman (63 kg) taking lithium for bipolar disorder presents with tremor and nausea. Current medications: lithium carbonate 300 mg three times daily, ibuprofen 600 mg three times daily started 1 week ago for back pain, and sertraline 50 mg daily. Labs: lithium level 1.9 mEq/L (reference 0.6–1.2), serum creatinine 1.3 mg/dL (reference 0.6–1.3). Allergy: none known. The ibuprofen was recommended by a clinic staff member without checking for interactions. Which medication error needs to be reported?
   Answer: Interaction oversight: nonsteroidal anti-inflammatory drug use can increase lithium concentrations; failure to screen and counsel is a reportable medication safety event Medication error identification and reporting capture unaddressed over-the-counter interactions with narrow therapeutic index drugs like lithium. The key patient-specific factor is ibuprofen initiation, which reduces lithium clearance, elevating levels and causing toxicity symptoms. Choice A best addresses the error as it identifies the interaction oversight and failure to screen or counsel, making it reportable. Choice B is incorrect because sertraline switch isn't indicated, and choice C is suboptimal as the lithium dose is standard. Choice D is wrong since lithium levels must be recorded formally. For similar errors, inquire about OTC use and educate on risks. Reporting promotes comprehensive profile reviews.
3. A 40-year-old man (75 kg) with asthma requests a refill for his rescue inhaler and reports using it multiple times daily for the past month. Current medications on profile: albuterol metered-dose inhaler 2 puffs every 4 to 6 hours as needed; no controller inhaler is listed. No allergies. Recent labs: none relevant. The pharmacy has been refilling albuterol monthly without notifying the prescriber about excessive use. Which medication error needs to be reported?
   Answer: Omission error: lack of appropriate controller therapy assessment/communication despite frequent rescue inhaler refills suggesting poor asthma control Medication error identification and reporting target omissions in assessing therapy appropriateness, like uncontrolled asthma indicated by frequent rescue use. The key patient-specific factor is monthly albuterol refills without controller therapy, suggesting poor control and need for escalation. Choice A best addresses the error as it highlights the failure to assess and communicate excessive rescue use to the prescriber. Choice B is incorrect because switching to epinephrine requires approval, and choice C is suboptimal as as-needed albuterol is standard in asthma. Choice D is wrong since weight isn't required for inhaler dispensing. For similar errors, monitor refill patterns and initiate prescriber contact. Reporting supports protocols for proactive intervention in chronic conditions.
4. A 57-year-old man (82 kg) is prescribed acetaminophen 1,000 mg every 6 hours as needed for pain after surgery. Current medications: acetaminophen as prescribed and a combination product he already uses at home: hydrocodone/acetaminophen 5 mg/325 mg, 2 tablets every 6 hours as needed. Labs: alanine aminotransferase 45 U/L (reference 7–56), aspartate aminotransferase 40 U/L (reference 10–40). Allergy: none known. The discharge medication reconciliation did not account for duplicate acetaminophen-containing products. Which medication error needs to be reported?
   Answer: Interaction oversight/duplicate therapy: unrecognized duplicate acetaminophen exposure increasing risk of hepatotoxicity; requires intervention and reporting Medication error identification and reporting entail spotting and logging issues like duplicate therapies to avert adverse events and refine clinical processes. The critical patient-specific factor is the concurrent use of standalone acetaminophen and a hydrocodone/acetaminophen combination, potentially exceeding the safe daily limit of 4 grams and risking hepatotoxicity, especially with normal but monitorable liver enzymes. Choice B best addresses this by recognizing the oversight in duplicate acetaminophen exposure during medication reconciliation, necessitating intervention, patient education, and formal reporting. Choice A is incorrect as omitting ibuprofen is not an error here, though it could be considered for multimodal pain management; choice C is suboptimal because switching to codeine/acetaminophen would still duplicate acetaminophen without resolving the issue. Choice D is wrong since acetaminophen does have a maximum daily dose, and duplication poses a significant safety concern. A general framework for managing similar errors involves thorough medication reconciliation at transitions of care, using tools like electronic alerts for duplicates. Clinicians should report these via systems like the hospital's incident reporting or national programs to analyze patterns and implement preventive strategies.
5. A 62-year-old woman (72 kg) is receiving vancomycin intravenously for cellulitis. Current medications: vancomycin 1,250 mg every 12 hours. Labs: serum creatinine increased from 0.9 to 1.8 mg/dL over 4 days (reference 0.6–1.3). No vancomycin levels were ordered or documented during therapy. Allergy: none known. Which medication error needs to be reported?
   Answer: Monitoring oversight: failure to monitor vancomycin exposure and renal function appropriately, contributing to nephrotoxicity risk Medication error identification and reporting target inadequate therapeutic monitoring for nephrotoxic agents like vancomycin to prevent renal injury. The key patient-specific factor is the absence of vancomycin levels and serial creatinine checks, allowing undetected accumulation and nephrotoxicity. Choice A best addresses the error as it identifies the monitoring oversight contributing to rising creatinine. Choice B is incorrect because vancomycin is appropriate for cellulitis, and choice C is suboptimal as the dose aligns with guidelines. Choice D is wrong since documentation is essential for accountability. For similar errors, follow pharmacokinetic monitoring protocols. Reporting encourages standardized ordering sets.
6. A 63-year-old female (weight 66 kg, height 158 cm) with chronic pain presents with excessive sedation and slowed breathing after starting a new medication yesterday. Current medications: oxycodone immediate-release 10 mg by mouth every 6 hours as needed (uses 3–4 doses/day), gabapentin 600 mg by mouth three times daily, and a new prescription for diazepam 5 mg by mouth three times daily for muscle spasm; allergies: none known. Labs: serum creatinine 0.9 mg/dL (0.6–1.3), alanine aminotransferase 22 units/L (7–56). The prescriber did not document counseling or risk mitigation, and no naloxone was offered. What is the most critical error in this scenario?
   Answer: Interaction oversight: benzodiazepine was added to chronic opioid therapy without addressing additive respiratory depression risk and safety measures (e.g., prescriber contact, counseling, documentation/reporting) This case demonstrates an interaction oversight error involving the dangerous combination of benzodiazepines with chronic opioid therapy without appropriate risk mitigation. The key patient-specific factor is the patient's chronic opioid use (oxycodone 3-4 times daily) now combined with diazepam, manifesting as respiratory depression (excessive sedation and slowed breathing). Option C correctly identifies this as an interaction oversight requiring immediate intervention, as the prescriber failed to address the additive CNS depression risk or implement safety measures like naloxone co-prescribing. Option A is incorrect because gabapentin and oxycodone don't have a significant pharmacokinetic interaction; the issue is the new benzodiazepine addition. Option B is wrong as taking diazepam with food for nausea is not the critical safety issue here. Option D is dangerously incorrect, advocating for increased opioid use and delayed reporting, which could result in fatal overdose. The framework for managing opioid-benzodiazepine combinations includes: (1) identifying all patients on chronic opioids before adding benzodiazepines, (2) implementing dose reductions when combination is necessary, (3) co-prescribing naloxone, (4) enhanced monitoring for respiratory depression, and (5) documenting risk-benefit discussions and safety measures.
7. A 52-year-old woman (90 kg, 165 cm) with hypothyroidism reports palpitations and weight loss after a refill. Current medications: levothyroxine 125 mcg daily (previously stable) and hydrochlorothiazide 25 mg daily. Labs: thyroid-stimulating hormone (TSH) 0.05 mIU/L (reference 0.4–4.0). Allergy: none known. The pharmacy record shows the prescriber intended levothyroxine 125 mcg daily, but the dispensed bottle contains 200 mcg tablets with directions to take 1 tablet daily. Which medication error needs to be reported?
   Answer: Dispensing error: wrong strength of levothyroxine (200 mcg) provided instead of prescribed 125 mcg Medication error identification and reporting capture dispensing inaccuracies like wrong strength that lead to overdosage and endocrine disruption. The key patient-specific factor is the dispensing of 200 mcg levothyroxine instead of 125 mcg, causing suppressed TSH and hyperthyroid symptoms. Choice C best addresses the error as it specifies the dispensing error in strength, directly linked to the patient's palpitations and weight loss. Choice A is incorrect because diet counseling isn't the priority over correcting the dose error, and choice B is suboptimal as furosemide substitution isn't warranted. Choice D is wrong since TSH monitoring is essential for levothyroxine therapy. For similar errors, implement double-checks for high-alert drugs like thyroid hormones. Reporting promotes error-tracking and process improvements like barcode scanning.
8. A 71-year-old man (70 kg) with chronic pain is prescribed morphine extended-release 30 mg every 12 hours. Current medications: morphine extended-release 30 mg every 12 hours (new) and gabapentin 300 mg three times daily. Allergy: none known. The prescription is entered correctly, but the label is printed as "morphine immediate-release 30 mg every 12 hours," and immediate-release tablets are dispensed. No relevant labs. How should this medication error be documented?
   Answer: Document the incorrect formulation, lot number, patient notification, prescriber notification, corrective action (recall/replace), and internal error report per policy Medication error identification and reporting require thorough documentation of dispensing errors, including corrective actions, to ensure accountability and prevention. The key patient-specific factor is the mislabeling and dispensing of immediate-release morphine instead of extended-release, risking overdose or inadequate pain control. Choice A best addresses the error by outlining comprehensive documentation of the error details, notifications, and actions per policy. Choice B is incorrect as it minimizes the error to patient dissatisfaction, and choice C is suboptimal by excusing the error. Choice D is wrong since immediate reporting is needed. For similar errors, follow recall procedures and patient outreach. Reporting builds robust error-tracking systems.
9. A 49-year-old man (86 kg) is prescribed allopurinol 300 mg daily for gout prophylaxis. Current medications: azathioprine 150 mg daily for inflammatory bowel disease and prednisone 5 mg daily. Labs: white blood cell count 4.2 $x10^3$/µL (reference 4.0–11.0), serum creatinine 1.0 mg/dL (reference 0.6–1.3), alanine aminotransferase 19 U/L (reference 7–56). Allergy: none known. The pharmacist verifies and dispenses allopurinol without reviewing interactions. Which medication error needs to be reported?
   Answer: Interaction oversight: allopurinol can increase azathioprine levels causing myelosuppression; pharmacist should intervene and document/report Medication error identification and reporting address hazardous interactions in immunosuppressed patients to avoid severe toxicity. The key patient-specific factor is allopurinol's inhibition of azathioprine metabolism, risking myelosuppression in a patient on chronic therapy. Choice A best addresses the error by noting the interaction oversight and need for intervention and reporting. Choice B is incorrect as colchicine isn't required indefinitely, and choice C is suboptimal since low-dose prednisone doesn't primarily cause gout. Choice D is wrong because reporting isn't limited to employers. In practice, screen immunosuppressant interactions rigorously. Reporting supports alert systems for high-risk pairs.
10. A 52-year-old female (weight 70 kg, height 168 cm) is discharged after an acute myocardial infarction. Discharge medications listed: aspirin 81 mg by mouth daily, atorvastatin 80 mg by mouth nightly, and nitroglycerin 0.4 mg sublingual as needed for chest pain; allergies: none known. The hospital course note states she received metoprolol tartrate during admission and tolerated it well, but no beta-blocker is included on the discharge medication list. Labs: serum creatinine 0.8 mg/dL (0.6–1.3), alanine aminotransferase 32 units/L (7–56), heart rate 72 beats/min, blood pressure 128/76 mm Hg. What is the most critical error in this scenario?
    Answer: Omission error: a beta-blocker indicated post–myocardial infarction was not included on the discharge regimen despite inpatient use and tolerance This case demonstrates an omission error where a guideline-recommended medication was not included in the discharge regimen despite clear indication and documented tolerance. The key patient-specific factor is the recent acute myocardial infarction, which requires beta-blocker therapy for mortality reduction unless contraindicated. Option B correctly identifies this as an omission error, as metoprolol was used during admission, tolerated well, but inexplicably excluded from discharge medications despite normal heart rate and blood pressure. Option A is incorrect because nitroglycerin is appropriately prescribed as-needed for angina, not scheduled post-MI. Option C is wrong because aspirin is correctly prescribed for secondary prevention and should never be documented as an allergy without true hypersensitivity. Option D is incorrect as discharge medication reconciliation errors must be addressed immediately to prevent patient harm, regardless of when the list was printed. The framework for preventing omission errors includes: (1) systematic medication reconciliation at transitions, (2) using standardized post-MI order sets, (3) pharmacist review of all cardiac discharge prescriptions, (4) documenting reasons for any guideline deviations, and (5) establishing quality checks for evidence-based therapies.
11. A 59-year-old man (95 kg, 178 cm) with type 2 diabetes is seen for follow-up and reports shaking and sweating several times daily since a medication change. Current medications: glipizide 10 mg twice daily, insulin glargine 20 units nightly, and clarithromycin 500 mg twice daily started 3 days ago for sinusitis. Labs: serum creatinine 0.9 mg/dL (reference 0.6–1.3), alanine aminotransferase 22 U/L (reference 7–56). Allergy: none known. The prescriber did not address a potential interaction when clarithromycin was added. What action should the pharmacist take to address the error?
    Answer: Contact the prescriber to modify therapy due to the interaction increasing sulfonylurea exposure and risk of hypoglycemia, and document/report the error per policy Medication error identification and reporting involve spotting interaction oversights that lead to adverse outcomes like hypoglycemia and ensuring prescriber communication for resolution. The key patient-specific factor is the addition of clarithromycin, a CYP3A4 inhibitor, to glipizide therapy, increasing sulfonylurea exposure and hypoglycemic risk. Choice B best addresses the error by recommending prescriber contact to modify therapy due to the interaction, aligning with reporting policies for patient safety. Choice A is incorrect as continuing without adjustment ignores the interaction's severity, and choice C is suboptimal because aspirin addition isn't indicated without cardiovascular assessment. Choice D is wrong since holding insulin glargine and restricting carbohydrates could worsen control without addressing the root cause. For similar errors, screen profiles for new additions and use interaction checkers routinely. Documenting and reporting builds a framework for team education and protocol enhancements.
12. A 45-year-old woman (70 kg) arrives at the pharmacy stating she picked up her refill for hydroxyzine 25 mg for itching but the tablets look different and she feels very sleepy after taking one dose. Her profile shows hydroxyzine 25 mg by mouth three times daily as needed. The dispensed bottle label reads hydralazine 25 mg by mouth three times daily. Vitals at the clinic earlier today: blood pressure 118/72 mmHg. Allergies: none known. Which medication error needs to be reported?
    Answer: Wrong drug dispensed: hydralazine was dispensed/labeled instead of hydroxyzine due to look-alike/sound-alike name confusion Medication error identification and reporting emphasize preventing mix-ups with look-alike/sound-alike medications to avoid unintended therapeutic effects and patient harm. The key patient-specific factor is the dispensing of hydralazine instead of hydroxyzine due to name similarity, leading to excessive sedation mistaken for the drug's effect. Choice A best addresses the error as it pinpoints the wrong drug dispensing error from name confusion, which caused the patient's symptoms. Choice B is incorrect because the hydroxyzine dose is within adult limits for itching, and choice C is suboptimal as adding a topical corticosteroid isn't necessary without assessing the itching's cause. Choice D is wrong since serum creatinine monitoring isn't required for hydroxyzine in patients without renal issues. In practice, use tall man lettering and separate storage for look-alike drugs to manage similar errors. Reporting to systems like MERP helps track patterns and implement safeguards like barcode verification.
13. A 64-year-old man (88 kg, 172 cm) with chronic kidney disease is prescribed gabapentin 600 mg by mouth three times daily for neuropathic pain. Current medications: gabapentin (new), amlodipine 10 mg daily, and acetaminophen 1,000 mg three times daily as needed. Labs: serum creatinine 2.8 mg/dL (reference 0.6–1.3), estimated creatinine clearance 18 mL/min. Allergy: none known. The pharmacist verifies the prescription without adjusting for renal function. What is the most critical error in this scenario?
    Answer: Incorrect dose: gabapentin was not adjusted for creatinine clearance 18 mL/min, increasing risk of central nervous system toxicity Medication error identification and reporting highlight unadjusted dosing in renal impairment for drugs like gabapentin to avert accumulation and toxicity. The key patient-specific factor is the creatinine clearance of 18 mL/min, necessitating a reduced gabapentin dose to prevent CNS effects. Choice A best addresses the error as it identifies the incorrect dose without renal adjustment, increasing toxicity risk. Choice B is incorrect because substituting with pregabalin requires prescriber approval, and choice C is suboptimal as ibuprofen addition isn't indicated without pain assessment. Choice D is wrong since weight is useful but not essential for gabapentin dosing. In practice, calculate renal function for all relevant prescriptions and consult dosing guidelines. Reporting fosters pharmacy protocols for mandatory renal checks.
14. A 58-year-old woman (68 kg) is prescribed methotrexate 15 mg by mouth once weekly for rheumatoid arthritis. Current medications: methotrexate 15 mg once weekly (new), folic acid 1 mg daily, and naproxen 250 mg twice daily as needed. Labs: serum creatinine 0.9 mg/dL (reference 0.6–1.3), aspartate aminotransferase 30 U/L (reference 10–40). Allergy: none known. The prescription is entered as methotrexate 15 mg by mouth once daily due to a data-entry mistake and is dispensed. What is the most critical error in this scenario?
    Answer: Incorrect dose/frequency: methotrexate was dispensed as daily instead of weekly, creating high risk of toxicity Medication error identification and reporting focus on data-entry mistakes leading to incorrect dosing frequencies for toxic drugs like methotrexate. The key patient-specific factor is the entry of daily instead of weekly methotrexate, risking cumulative toxicity like myelosuppression. Choice C best addresses the error as it identifies the incorrect dose/frequency dispensing, posing high toxicity risk. Choice A is incorrect because Latin abbreviations aren't required, and choice B is suboptimal by delaying correction. Choice D is wrong since naproxen interaction is manageable, not primary. In practice, verify high-alert drug frequencies with double-checks. Reporting drives system changes like electronic safeguards.
15. A 76-year-old woman (52 kg, 158 cm) is admitted for nausea and visual halos. Current medications: digoxin 0.25 mg daily, furosemide 40 mg daily, and potassium chloride 20 mEq daily. Labs: potassium 2.9 mEq/L (reference 3.5–5.0), serum creatinine 1.6 mg/dL (reference 0.6–1.3), digoxin level 2.6 ng/mL (reference 0.5–2.0). Allergy: none known. Her outpatient chart shows no digoxin level or renal function monitoring for over a year despite chronic therapy. Which medication error needs to be reported?
    Answer: Monitoring oversight: inadequate monitoring of digoxin level and renal function leading to toxicity risk Medication error identification and reporting target lapses in ongoing monitoring for high-risk medications like digoxin to prevent toxicity in vulnerable patients. The key patient-specific factor is the lack of digoxin level and renal function checks over a year, combined with hypokalemia, exacerbating toxicity risks. Choice B best addresses the error as it identifies inadequate monitoring leading to elevated digoxin levels and symptoms like nausea and visual halos. Choice A is incorrect because reporting isn't limited to insurance plans, and choice C is suboptimal as potassium chloride is appropriate, not needing replacement with phosphate. Choice D is wrong since nausea indicates digoxin toxicity, not an expected furosemide effect. In practice, establish monitoring protocols for digoxin including regular levels and electrolytes. Reporting such oversights promotes quality improvement initiatives like automated reminders.
16. A 33-year-old man (80 kg) is prescribed isotretinoin for severe acne. Current medications: isotretinoin 40 mg twice daily newly prescribed. Labs: alanine aminotransferase 62 U/L (reference 7–56), triglycerides 410 mg/dL (reference <150). Allergy: none known. The prescriber's note includes the labs, but the pharmacy receives a prescription without documentation of required baseline monitoring plan or follow-up labs. How should this medication error be documented?
    Answer: Document the missing monitoring plan (lipids and liver enzymes), communication with prescriber, and the disposition (held/clarified) per pharmacy error-reporting policy Medication error identification and reporting require documenting failures in required monitoring for teratogenic drugs like isotretinoin to ensure compliance and prevent harm. The key patient-specific factor is the absence of a documented baseline monitoring plan for lipids and liver enzymes despite abnormal labs, violating isotretinoin safety protocols. Choice C best addresses the error by emphasizing documentation of the missing plan, prescriber communication, and disposition to adhere to error-reporting policies. Choice A is incorrect as abnormal triglycerides are a known isotretinoin risk requiring monitoring, and choice B is suboptimal by ignoring safety monitoring. Choice D is wrong since personal notebooks avoid formal records needed for accountability. For similar errors, verify REMS requirements before dispensing and collaborate with prescribers. Reporting enhances systemic adherence to risk management programs.
17. A 66-year-old man (92 kg, 180 cm) with heart failure is discharged on lisinopril 20 mg daily, spironolactone 25 mg daily, and potassium chloride 20 mEq daily. Labs at discharge: potassium 5.6 mEq/L (reference 3.5–5.0), serum creatinine 1.4 mg/dL (reference 0.6–1.3). Allergy: none known. The discharge medication list includes potassium chloride despite hyperkalemia and concurrent potassium-sparing therapy. Which medication error needs to be reported?
    Answer: Interaction oversight/duplicate effect: potassium supplementation was continued despite hyperkalemia and use of spironolactone and lisinopril Medication error identification and reporting include duplicate therapies causing electrolyte imbalances in heart failure patients. The key patient-specific factor is continuing potassium supplementation with hyperkalemia and potassium-sparing agents like spironolactone and lisinopril. Choice A best addresses the error as it points to the oversight of additive hyperkalemic effects, risking arrhythmias. Choice B is incorrect because spironolactone is appropriate in heart failure, and choice C is suboptimal as INR isn't relevant for lisinopril. Choice D is wrong since potassium 5.6 mEq/L indicates hyperkalemia. For similar errors, review profiles for additive effects and adjust accordingly. Reporting informs guidelines for electrolyte management.
18. A 70-year-old male (weight 82 kg, height 172 cm) with type 2 diabetes picks up refills. Current medications on profile: insulin glargine 30 units subcutaneously nightly, metformin 1000 mg by mouth twice daily, and lisinopril 20 mg by mouth daily; allergies: none known. The electronic prescription for insulin glargine was written for "inject 30 units nightly," but during data entry it was documented as "inject 80 units nightly," and the label reflects 80 units; the patient has not administered the new supply yet. Recent labs: serum creatinine 1.0 mg/dL (0.6–1.3), hemoglobin A1c 7.4% (goal individualized). How should this medication error be documented?
    Answer: Document as a near-miss dispensing/documentation error (wrong dose on label), correct the label before use, notify the patient and prescriber as needed, and file an internal safety report per policy This case represents a near-miss dispensing error where an incorrect dose was entered on the label but caught before patient administration. The key patient-specific factor is the significant dose discrepancy (30 units prescribed vs 80 units on label) for insulin, which could cause severe hypoglycemia if administered. Option A correctly identifies this as a near-miss dispensing/documentation error requiring immediate label correction, appropriate notifications, and internal safety reporting per policy to prevent future occurrences. Option B is incorrect because all medication errors, including near-misses, must be reported through safety systems to identify patterns and prevent harm. Option C is wrong because this is not an adverse drug reaction but a dispensing error; hypoglycemia from correct insulin use differs from errors in dispensing. Option D is incorrect as this is a pharmacy system error, not patient nonadherence, and patients cannot be expected to catch all dispensing errors. The framework for managing near-miss errors includes: (1) immediate correction before reaching the patient, (2) transparent communication with patients when errors are discovered, (3) formal documentation in error reporting systems, (4) root cause analysis of data entry processes, and (5) implementation of verification steps for high-alert medications.
19. A 23-year-old woman (55 kg) with a urinary tract infection is prescribed nitrofurantoin 100 mg twice daily for 5 days. Current medications: none. Labs: serum creatinine 1.9 mg/dL (reference 0.6–1.3), estimated creatinine clearance 28 mL/min. Allergy: sulfonamides (hives). The prescription is dispensed without evaluating renal function appropriateness. What action should the pharmacist take to address the error?
    Answer: Contact the prescriber to recommend an alternative agent due to reduced efficacy and increased risk with creatinine clearance 28 mL/min, and document/report the renal dosing oversight Medication error identification and reporting address inappropriate drug selection in renal impairment to ensure efficacy and safety. The key patient-specific factor is creatinine clearance of 28 mL/min, where nitrofurantoin has reduced efficacy and increased toxicity risk. Choice B best addresses the error by recommending prescriber contact for alternatives and reporting the dosing oversight. Choice A is incorrect as nitrofurantoin isn't safe short-term below 30 mL/min, and choice C is suboptimal due to sulfonamide allergy. Choice D is wrong since proactive reporting prevents harm. In practice, assess renal function against contraindications before dispensing. Reporting strengthens checks for at-risk populations.
20. A 61-year-old man (84 kg) with atrial fibrillation is on apixaban 5 mg twice daily. He is prescribed ketoconazole 200 mg daily for a fungal infection. Current medications: apixaban 5 mg twice daily, ketoconazole 200 mg daily (new), and diltiazem extended-release 240 mg daily. Labs: serum creatinine 1.0 mg/dL (reference 0.6–1.3), alanine aminotransferase 25 U/L (reference 7–56). Allergy: none known. The pharmacist processes the ketoconazole without assessing interaction risk. What action should the pharmacist take to address the error?
    Answer: Contact the prescriber because ketoconazole can significantly increase apixaban exposure; recommend an alternative antifungal or apixaban adjustment per labeling and document/report the interaction oversight Medication error identification and reporting involve intervening in potent interactions for anticoagulants to prevent bleeding risks. The key patient-specific factor is ketoconazole's strong CYP3A4 inhibition increasing apixaban exposure in a patient on diltiazem, another inhibitor. Choice B best addresses the error by recommending prescriber contact for alternatives or adjustments and reporting the oversight. Choice A is incorrect as dose separation doesn't mitigate this interaction, and choice C is suboptimal because switching to aspirin ignores atrial fibrillation needs. Choice D is wrong since this is an error, not just an adverse reaction. In practice, use interaction tools and hold dispensing until resolved. Reporting enhances safety nets for high-risk combinations.

Start this quiz